This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

A 53-year-old man presented with acute loss of vision, negative scotoma and dyschromatopsia in his left eye. He reported contact with people with severe respiratory syndrome -coronavirus-2 (SARS-CoV-2) 8 days prior symptoms. Funduscopic examination revealed several retinal hemorrhages. Spectral-domain optical coherence tomography showed lesions consistent with acute macular neuroretinopathy and paracentral acute middle maculopathy. Quickly after his presentation, SARSCov-2 was confirmed by chest computed tomography-scan and RT-PCR in this patient. Thrombotic complications associated with Covid-19 infection have high incidence and may involve the retina. We described a case of retinal involvement associated with Covid-19 infection. Précis: Funduscopic examination revealed retinal hemorrhages in a man with loss of vision. Optical coherence tomography showed an acute macular neuroretinopathy and paracentral acute middle maculopathy. Coronavirus disease was confirmed by chest computed tomography-scan and RT-PCR.

Highlights d BTN2A1 expression in cancer cells correlates with Vg9Vd2 T cell cytotoxicity d BTN2A1 interacts with BTN3A1/3A2/3A3, leading to enhanced plasma membrane export d B30.2 domains of both BTN3A1 and BTN2A1 are required for pAg responsiveness d Anti-BTN2A1 mAbs blocking Vg9Vd2TCR binding antagonize Vg9Vd2 T cell cytotoxicity

Severe coronavirus disease 2019 , due to the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), may be associated with mild thrombocytopenia, 1,2 and some COVID-19-induced immune thrombocytopenia (ITP) cases have been reported. 3,4 Some reports suggest that patients with pre-existing ITP may experience a relapse 5 in the case of SARS-CoV-2 infection that could be prevented by vaccination. However, a growing number of de novo ITP occurring after anti-SARS-CoV-2 vaccination are being reported with mRNA-based vaccines. In a recent series, 6 20 patients who received either BNT162b2 (Comirnaty â ) or mRNA-1273 (SpikeVax â ) vaccines had new-onset thrombocytopenia after the first injection (median time: 5 days), usually associated with bleeding and low platelet counts (median: 2 9 10 9 /l). The incidence of vaccine-induced thrombocytopenia remains difficult to assess precisely as no routine blood count is recommended after vaccination. However, it appears very low, with >20 million people vaccinated in the United States with at least one dose at the time this paper 6 was submitted. However, whether patients with ITP have a risk of relapse after anti-SARS-CoV-2 vaccination remains a matter of debate. In France, the National Reference Centre for Adult Immune Cytopenia proposed that anti-SARS-CoV-2 vaccination should be considered in patients with ITP and that a platelet count should be obtained 1 week after each vaccine injection in order to detect ITP relapse. In the present study, we assessed the evolution of a cohort of patients with ITP that received anti-SARS-CoV-2 vaccination.We conducted an observational study in four French referral centres from January 2021 to June 2021. Inclusion criteria were patients aged >18 years with a previous ITP diagnosis (primary or secondary) according to international criteria 7 and receiving at least one anti-SARS-CoV-2 vaccine injection. All these patients were already enrolled in the prospective CARMEN-France registry and were not opposed to real-world data collection about ITP management. All clinical and biological data used in the present study were already recorded in the registry (authorisation number 2012-438 from the French national agency regulating data protection).From January to June 2021, 92 adult patients with ITP (55 women, 59Á8%), with a median [interquartile range (IQR), range] age of 69 [19, years (Table SI) were selected. In all, 78 patients had primary ITP (85%), and two had a history of COVID-19-associated ITP 1 year previously. At the time of first vaccine dose, the median (IQR, range)

Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug?

No abstract

No abstract

No abstract